Search
for

    Learn

    5 / 12 results

      learn Bicalutamide

      a nonsteroidal anti-androgen, most commonly used orally for women

      learn RU58841

      a potent but unapproved and potentially problematic topical anti-androgen

      learn Finasteride

      Frontline, gold standard treatment for combatting androgenic alopecia

      learn Fluridil

      a topical anti-androgen with less systemic involvement

    Research

    5 / 1000+ results

    Community Join

    5 / 1000+ results

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

      in Research/Science  136 upvotes 7 months ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

      community Kintor’s GT20029 Phase 1 success

      in Update  73 upvotes 1 year ago
      Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.